10x Genomics (TXG) Change in Accured Expenses (2018 - 2026)

10x Genomics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $3.1 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 20.49% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at -$2.4 million (up 71.88% YoY), while the FY2025 annual figure was $7.6 million, up 160.04% from the prior year.
• Change in Accured Expenses came in at $3.1 million for Q2 2026 at 10x Genomics, up from -$21.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.5 million in Q3 2023 to a low of -$21.0 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $484166.7, with a median of $3.5 million recorded in 2025.
• Year-over-year, Change in Accured Expenses soared 651.57% in 2022 and slumped 125.73% in 2024.
• Over 5 years, Change in Accured Expenses stood at $6.5 million in 2022, then soared by 194.63% to $19.1 million in 2023, then slumped by 77.03% to $4.4 million in 2024, then surged by 299.77% to $17.6 million in 2025, then sank by 82.24% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $3.1 million in Q2 2026, -$21.0 million in Q1 2026, and $17.6 million in Q4 2025.